Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides
Leong L. Ng, MD*,*,
Ian W. Loke, MB*,
Joan E. Davies, PhD*, ,
Sandeep Geeranavar, BSc*,
Kamlesh Khunti, MD ,
Margaret A. Stone, PhD ,
Derek T. Chin, MB and
Iain B. Squire, MD*
* Department of Cardiovascular Sciences, University of Leicester, United Kingdom
Department of Health Sciences, University of Leicester, United Kingdom
Department of Cardiology, Glenfield Hospital, Leicester, United Kingdom

View larger version (17K):
[in a new window]
|
Figure 1 The receiver-operating characteristic curves for plasma and urinary N-terminal pro-brain natriuretic peptide (N-BNP) and the plasma/urinary N-BNP product in left ventricular systolic dysfunction detection. Solid line = urinary N-BNP; dotted line = urinary x plasma N-BNP; dashed line = plasma N-BNP.
|
|

View larger version (32K):
[in a new window]
|
Figure 2 A scatterplot of urinary and plasma N-terminal pro-brain natriuretic peptide (N-BNP) in those subjects with a positive urine test (defined as >10.7 fmol/ml). Normal subjects (open circles) or subjects with left ventricular systolic dysfunction (solid triangles).
|
|

View larger version (14K):
[in a new window]
|
Figure 3 The receiver-operating characteristic curves for plasma and urinary N-terminal pro-brain natriuretic peptide (N-BNP) and the plasma/urinary N-BNP product in left ventricular systolic dysfunction detection within a high-risk group (age >65 years, hypertension, ischemic heart disease).
|
|

View larger version (19K):
[in a new window]
|
Figure 4 Stability of urinary N-terminal pro-brain natriuretic peptide (N-BNP) when stored at room temperature for up to 72 h.
|
|
|